Launch of Zeposia^® Announced

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD

The commercial launch and availability of Zeposia^® (ozanimod) for the treatment of adults with relapsing forms of multiple sclerosis (RMS) was officially announced today. Initially approved by the United States Food and Drug Administration (FDA) on March 25, 2020, the makers of Zeposia, Bristol Myers Squibb, made the decision to delay its launch in light of the COVID-19 pandemic and the tremendous burden on the country’s healthcare system.

Given once daily as a 0.92 mg oral pill, Zeposia’s approval includes the treatment of clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary-progressive MS (SPMS). According to Bristol Myers Squibb, the ZEPOSIA 360 Support™ Program provides pre-initiation support, access support, and financial support. Terms, conditions, and eligibility criteria apply. More information is available at Zeposia.com. Individuals may also call (833) ZEPOSIA or (833) 937-6742.

Please see MSAA’s news article, “FDA Approves Zeposia® (ozanimod) for the Treatment of Relapsing Forms of MS” for full details on the approval of Zeposia. For general information or to speak with a trained Client Services Specialist, please call MSAA’s Helpline at (800) 532-7667, extension 154. Questions to MSAA’s Client Services department may also be emailed to MSquestions@mymsaa.org.

Written by Susan Wells Courtney, MSAA Senior Writer
Reviewed by Dr. Barry A. Hendin, MSAA Chief Medical Officer